Latest news for Peugeot Invest (OTC:SFFFF) Stock

Peugeot Invest is an investment company. It holds interests in several industrial companies; however, PSA Peugot Citroen group is its main asset. The group invests in other opportunities for diversification purposes. Traditionally, the company seeks to be a long-term minority shareholder and invest in companies with similar characteristics. Portfolio companies tend to be family-owned and among the leading players in their industry. Other investments include private equity funds that FFP makes co-investments alongside. For companies within its portfolio, the company takes a seat on the board of directors or supervisory boards to take on an active role within the investee.

Peugeot Invest

Goldman Sachs analyst Neil Mehta maintains PBF Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBF#NYSE">PBF</a>) with a Neutral and lowers the price target from $38 to $34.

News

Price Target

Analyst Ratings

Goldman Sachs Maintains Neutral on PBF Energy, Lowers Price Target to $34

BMO Capital analyst Kenneth Lee downgrades BrightSphere Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSIG#NYSE">BSIG</a>) from Outperform to Sector Perform and raises the price target from $30 to $33.

Downgrades

BrightSphere Investment Group plc Ordinary Shares

BSIG

BMO Capital Downgrades BrightSphere Investment to Sector Perform, Raises Price Target to $33

Biotech

General

IMMX

Immix Biopharma Reports 75% Complete Response Rate And 31.5-Month Ongoing Best Response Duration For CAR-T NXC-201 In Relapsed/Refractory AL Amyloidosis At ASH 2024, Highlighting Phase 1/2 Data With Median Four Prior Therapy Lines

On Monday, Chimerix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) announced that, following extensive dialogue with the FDA, the company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone for recurrent H3 K27M-mutant diffuse glioma in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42399560/chimerix-to-submit-dordaviprone-for-accelerated-approval-to-u-s-fda-for-patients-with-recurrent-h3" rel="noreferrer noopener">the U.S. before year-end</a>.
A glioma is&nbsp;a tumor that originates in the glial cells of the brain or spinal cord and is the most common primary brain tumor.
Chimerix stock is trading higher on a strong session volume of 4.31 million, compared to an average volume of 497.04K, as per data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
The following recent program milestones and additional supportive data were extensively discussed with the FDA and will be included in the NDA:
<ul>
<li>Substantial enrollment of the Phase 3 ACTION study.</li>
<li>Phase 2 objective response rate of the 50-patient primary efficacy analysis as the primary basis of efficacy in the NDA.</li>
<li>Several response assessments, under which dordaviprone demonstrated an objective response rate of 28%, a median duration of response of 10.4 months, and a median time to response of 4.6 months.</li>
<li>Additional clinical data sets and patient narratives supportive of the primary efficacy analysis.</li>
<li>Clinical and nonclinical demonstration of dordaviprone-driven reversal of the central hallmark of H3 K27M-mutant glioma, H3K27 trimethyl loss.</li>
<li>Comprehensive safety database of glioma patients and healthy volunteers that supports a favorable benefit/risk profile.</li>
<li>Comprehensive clinical pharmacology and chemistry, manufacturing, and controls (CMC) studies.</li>
</ul>
Chimerix will request a Priority Review for the NDA. If granted, the resulting six-month FDA review period is expected to result in a potential initial Prescription Drug User Fee Act (PDUFA) action date in the third quarter of 2025.
Dordaviprone has received Rare Pediatric Disease Designation for H3 K27M-mutant glioma and is eligible to apply for a Rare Pediatric Disease Priority Review Voucher.
&#8220;In anticipation of a potential approval, we have bolstered our commercial leadership team and will be ready for a U.S. launch as early as the third quarter of 2025, pending application acceptance and Priority Review, if granted,&#8221; said Mike Andriole, CEO of Chimerix.
Price Action: CMRX stock is up 153.20% at $2.19 at last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42397286/biogen-downgraded-on-pipeline-setbacks-and-leqembi-sales-slowdown" target="_blank" rel="noreferrer noopener">Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown</a></li>
</ul>

Health Care

Movers

CMRX

Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?

Trading Ideas

SATL

Satellogic Shares Halted To The Downside; Stock Now Down -20.25%

VSTS

Advent, Apollo Among Buyout Firms That Are Bidding For Vestis

Ohio Supreme Court Sides With CVS , Walmart And Walgreens In Appeal Of $650.9M Opioid Trial Judgement

Metagenomi Shares Halted On Circuit Breaker To The Upside, Stock Now Up 11.8%

VIAV

Windstream Wholesale And VIAVI Complete World's First 800G Transatlantic Network Trial, Spanning 8,500 KM Between Chicago And London, Using Nokia's PSI-M Platform And VIAVI's Advanced Testing Solutions To Validate Error-Free High-Speed Transmission And Service Stability

T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) has outperformed the market over the past 10 years by 13.19% on an annualized basis producing an average annual return of 25.0%. Currently, T-Mobile US has a market capitalization of $271.55 billion. 
Buying $1000 In TMUS: If an investor had bought $1000 of TMUS stock 10 years ago, it would be worth $9,063.76 today based on a price of $234.00 for TMUS at the time of writing.
<h3>T-Mobile US's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733841060_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TMUS

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) has outperformed the market over the past 10 years by 14.27% on an annualized basis producing an average annual return of 26.09%. Currently, Lam Research has a market capitalization of $99.47 billion. 
Buying $100 In LRCX: If an investor had bought $100 of LRCX stock 10 years ago, it would be worth $996.43 today based on a price of $77.31 for LRCX at the time of writing.
<h3>Lam Research's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733841056_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LRCX

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Vail Resorts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) reported better-than-expected sales for its <a href="https://www.benzinga.com/quote/MTN/earnings">first quarter on Monday</a>.
The company posted a quarterly loss of $4.61 per share which beat the analyst consensus estimate of a loss of $5.05 per share. The company reported quarterly sales of $260.27 million which beat the analyst consensus estimate of $254.00 million.
Kirsten Lynch, Chief Executive Officer, said, &#8220;Our first fiscal quarter historically operates at a loss, given that our North American and European mountain resorts are generally not open for ski season. The quarter&#8217;s results were driven by winter operations in Australia and summer activities in North America, including sightseeing, dining, retail, lodging, and administrative expenses."
Vail Resorts raised its FY25 net income guidance from $224 million-$300 million to $240 million-$316 million.
Vail Resorts shares slipped 0.02% to close at $190.67 on Monday.
These analysts made changes to their price targets on Vail Resorts following earnings announcement.
<ul>
<li>Mizuho analyst Ben Chaiken maintained Vail Resorts with an Outperform and raised the price target from $222 to $227.</li>
<li>Morgan Stanley analyst Megan Alexander maintained the stock with an Equal-Weight and raised the price target from $182 to $197.</li>
<li>Barclays analyst Brandt Montour maintained Vail Resorts with an Underweight and raised the price target from $155 to $165.</li>
</ul>
Considering buying MTN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10092927/image-82-1024x574.png" alt="" class="wp-image-685377" style="width:552px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10092927/image-82-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10092927/image-82-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10092927/image-82-768x430.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10092927/image-82.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42405361/sp-500-nasdaq-retreat-from-record-highs-investor-sentiment-declines-fear-greed-index-remains-in-neutral-zone">S&amp;P 500, Nasdaq Retreat From Record Highs As Nvidia Declines Over Chinese Antitrust Concerns: Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>

Earnings

Markets

These Analysts Boost Their Forecasts On Vail Resorts Following Q1 Results

Bakkt Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) short percent of float has risen 10.27% since its last report. The company recently reported that it has 907 thousand shares sold short, which is 14.39% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Bakkt Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733841023_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Bakkt Hldgs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Bakkt Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Bakkt Hldgs's peer group average for short interest as a percentage of float is 2.13%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Peering Into Bakkt Hldgs's Recent Short Interest

Lantheus Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NYSE">LNTH</a>) short percent of float has risen 6.28% since its last report. The company recently reported that it has 4.45 million shares sold short, which is 8.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lantheus Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733841017_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lantheus Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lantheus Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lantheus Holdings's peer group average for short interest as a percentage of float is 6.33%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

LNTH

How Is The Market Feeling About Lantheus Holdings?

Howmet Aerospace's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) short percent of float has risen 5.31% since its last report. The company recently reported that it has 7.78 million shares sold short, which is 2.18% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.15 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Howmet Aerospace Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733841012_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Howmet Aerospace has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Howmet Aerospace's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Howmet Aerospace's peer group average for short interest as a percentage of float is 3.31%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(HWM) - Analyzing Howmet Aerospace's Short Interest

D. Boral Capital analyst Jason Kolbert downgrades CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) from Buy to Hold.

CRVO

D. Boral Capital Downgrades CervoMed to Hold

Shares of U.S.-listed Chinese companies took a hit on Tuesday, giving back much of Monday's rally as disappointing trade data highlighted persistent challenges in the <a href="https://www.benzinga.com/topic/china">world's second-largest economy. </a>
China&#8217;s November trade data continued to paint a stark picture of an economy grappling with a prolonged slowdown. 
Imports fell as domestic demand remains weak, while exports surged, particularly to the U.S., driven by manufacturers racing to beat potential new tariffs under President-elect Donald Trump&#8216;s administration.
Weak domestic consumption and a deepening housing market crisis have clouded investor optimism, despite Beijing&#8217;s promises of fiscal and monetary stimulus for 2024.
<h3 class="wp-block-heading">Chinese Imports Dive, Exports</h3>
Imports to China slumped 3.9% year-over-year in November to $214.87 billion, marking the steepest decline in nine months. This contraction, worse than October's 2.3% drop and far below expectations of 0.3% growth, underscores a softening domestic economy plagued by weak consumption and an ongoing housing crisis.
In the first 11 months of 2024, imports edged up just 1.2% to $2.36 trillion, highlighting lackluster demand in a country long touted as a key driver of global trade.
Meanwhile, exports grew 6.7% year-over-year to $312.31 billion in November, missing forecasts of 8.5% growth and sharply down from October&#8217;s 12.7% surge. Despite marking the eighth consecutive month of export expansion and a 26-month high in export value, the numbers tell a more nuanced story.
The export surge reflects manufacturers scrambling to front-load shipments to the U.S. in anticipation of new tariffs. Overall, Chinese exports to the U.S. rose by 8% last month.
"Chinese companies rushed to get goods to the U.S. before new tariffs are imposed," said Saxo Bank&#8217;s head of commodity strategy Ole Hansen.
China&#8217;s trade surplus ballooned to $97.44 billion in November, up from $69.45 billion a year earlier and above market expectations of $95 billion. This was the largest surplus since June, fueled by the export growth and plummeting imports.
While a larger surplus might seem like a win, it signals deeper troubles. A high trade surplus is a symptom of weak domestic demand, as subdued consumption is curbing imports while China increasingly relies on exports for growth.
<h3 class="wp-block-heading">Stimulus Skepticism Grows, Geopolitical Risks Add Pressure</h3>
The weak trade data dampened enthusiasm for Beijing's recently announced fiscal and monetary stimulus measures for 2024. "China sits on 300% total debt-to-GDP and flirts with deflation," macro analyst Alfonso Peccatiello, known as @macroalf, wrote on X. "They better get their act together for real this time."
Markets appear skeptical about Beijing's ability to deliver meaningful economic recovery. Andreas Steno Larsen, chief investment officer at Steno Global Macro Fund, commented, "Markets are likely less inclined to buy into the Chinese stimulus story this time due to a lack of credibility."
Adding to economic woes, geopolitical tensions are flaring. Taiwan raised its alert level as nearly 90 Chinese navy and coast guard vessels were reportedly massing near Taiwan, southern Japan, and the East and South China Seas, according to Reuters.
<h3 class="wp-block-heading">Top Chinese Stocks Reverse Course</h3>
PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) fell 4% in premarket trading after a stunning 10.5% surge on Monday. 
Alibaba Group Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) dropped 2.6% following a 7.5% gain, and JD.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) slid 3.6%, erasing some of its 11% rally from the previous session.
Chinese electric vehicle makers also saw red. Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) dropped 3.1%, while NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) tumbled 4.4%, reversing Monday&#8217;s gains of 8% and 12.4%, respectively.
The iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>) tumbled 4%, partially erasing Monday&#8217;s 8.2% spike. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42409492/teslas-2nd-best-week-in-china-in-2024-boosts-q4-prospects">Tesla&#8217;s 2nd Best Week in China In 2024 Boosts Q4 Prospects</a></li>
</ul>
Photo: ambient_pix/Shutterstock.com

Asia

Macro Economic Events

Global

Econ #s

Economics

Tech

ETFs

BABA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Chinese Stocks Sink On Weak Trade Data Amid Rush 'To Get Goods To The US' Before Tariffs

Offerings

Solaris Energy Infrastructure Prices Public Offering Of 6.5M Class A Shares At $24.75 Each For Net Proceeds Of $156M

uniQure N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) shares are rising following a significant development in its <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42409488/uniqure-announces-alignment-with-fda-on-key-elements-of-accelerated-approval-pathway-for-amt-130-i" rel="noreferrer noopener">efforts to treat Huntington&#8217;s disease</a>.
The company has made a key breakthrough with its treatment, AMT-130. The company announced that the FDA has agreed on important elements for an accelerated approval pathway for AMT-130, a potential therapy aimed at slowing the disease&#8217;s progression.
The FDA&#8217;s decision followed discussions regarding data from ongoing Phase I/II clinical studies. The FDA has confirmed that the data, compared to a natural history control, can be used for the Biologics License Application (BLA), bypassing the need for additional pre-submission studies.
Huntington&#8217;s disease is a rare, inherited neurodegenerative disorder that causes progressive motor dysfunction, cognitive decline, and behavioral changes.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42408217/us-stocks-to-open-lower-as-traders-await-slew-of-data-us-listed-chinese-stocks-in-focus-following-stimulus-pledge" rel="noreferrer noopener">US Stocks Likely To Open Lower As Traders Await Slew Of Data: US-Listed Chinese Stocks In Focus Following Stimulus Pledge</a>
This latest agreement marks a crucial milestone for the Huntington&#8217;s disease community, as AMT-130 could soon become a groundbreaking therapy.
The FDA also acknowledged reductions in neurofilament light chain (NfL), a biomarker of neurodegeneration, as supportive evidence of the therapy&#8217;s potential benefits.
uniQure continues its efforts in advancing AMT-130, with BLA readiness activities underway and plans to engage further with the FDA in early 2025.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, QURE stock has gained over 2% in the past year. Investors can gain exposure to the stock via Virtus LifeSci Biotech Clinical Trials ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBC#NYSE">BBC</a>).
Price Action: QURE shares are trading higher by 87.8% to $13.70 in the premarket session on Tuesday.
Read Next:
<ul>
<li><a href="http://trump's%20deregulation%20efforts%20to%20benefit%20energy,%20oil%20and%20gas%20sectors,%20while%20ai%20frenzy%20will%20boost%20faang%20stocks%20and%20nvidia,%20says%20fintech%20insider/" target="_blank" rel="noreferrer noopener">Trump&#8217;s Deregulation Efforts To Benefit Energy, Oil And Gas Sectors, While AI Frenzy Will Boost FAANG Stocks And Nvidia, Says Fintech Insider</a></li>
</ul>
Photo via Shutterstock.

Equities

QURE

Why Is uniQure Stock Skyrocketing On Tuesday?

D. Boral Capital analyst Jason Kolbert maintains Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) with a Buy and maintains $29 price target.

Comments

Peugeot Invest

News

Latest news for Peugeot Invest (OTC:SFFFF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga